Cancer clinical trials in the region Occitanie

391 currently recruiting clinical trials
Region Occitanie

Phase 3 Lung cancer #NCT06890598 #2024-512302-25-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Required genetic anomalies
KRAS G12C
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy Radiotherapy
Excluded genetic anomalies
ALK EGFR
14 recruiting sites
Eli Lilly et compagnie
Phase 3 Lung cancer #NCT06890598 #2024-512302-25-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Localized Locally Advanced
Required genetic anomalies
KRAS G12C
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Surgery Immunotherapy Chemotherapy
Excluded genetic anomalies
ALK EGFR
14 recruiting sites
Eli Lilly et compagnie
Phase 3 Breast cancer #NCT05633654
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Chemotherapy Radiotherapy
Required previous treatments at advanced or metastatic stage
Surgery Chemotherapy Radiotherapy
Excluded genetic anomalies
BRCA 1/2
Excluded previous treatments at localized stage
Systemic Treatment-Naive Immunotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy Antibody Drug Conjugates (ADC)
15 recruiting sites
Gilead Sciences
Phase 3 Cervical / Vulvar / Vaginal cancer #NCT03534713
Required histologic types
Cervical cancer
Required histologic sub types
Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma
Required FIGO stages
Stage I Stage II Stage III Stage IV
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy
11 recruiting sites
Hôpital universitaire de Toulouse
Phase 3 Cervical / Vulvar / Vaginal cancer #NCT05581121
Required histologic types
Cervical cancer
Required histologic sub types
Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma
Required FIGO stages
Stage III
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Radiotherapy
24 recruiting sites
Institut Claudius Regaud
Phase 3 Cervical / Vulvar / Vaginal cancer #NCT05078047
Required histologic types
Cervical cancer
Required disease stage
Locally Advanced Metastatic
24 recruiting sites
UNICANCER
Phase 3 Acute leukemia #NCT07007312 #2025-521314-25-00
Required histologic types
Acute myeloid leukemia (AML)
Required genetic anomalies
KMT2A NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
BCR-ABL
11 recruiting sites
Kura Oncologie, Inc.
Phase 3 Acute leukemia #NCT07007312 #2025-521314-25-00
Required histologic types
Acute myeloid leukemia (AML)
Required genetic anomalies
NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
BCR-ABL
11 recruiting sites
Kura Oncologie, Inc.
Phase 3 Penile cancer and germ cell tumors #NCT05874063 #2022-502426-41-00
Required histologic types
Germ cell tumor
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required IGCCCG prognostic scores
Good prognosis Intermediate prognosis
18 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Head and neck cancer #NCT06525220 #2023-510323-30-00
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 20) CPS Positive (X >= 20)
14 recruiting sites
Merus